Ortho Evra (Norelgestromin, Ethinyl Estradiol) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Ortho Evra

Birth Control (Types and Options) »

Introduction to birth control types and options

If a woman is sexually active and she is fertile — physically able to become pregnant — she needs to ask herself, "Do I want to become pregnant now?" If her answer is "No," she must use some method of birth control (contraception).

If a woman does not want to get pregnant at this point in her life, does she plan to become pregnant in the future? Soon? Much later? Never? Her answers to these questions can determine the method of birth control that she and her male sexual partner use — now and in the future.

There are a number of different ways to describe birth control. Terms include contraception, pregnancy prevention, fertility control, and family planning. But no matter what the process is called, sexually active people can choose from a plethora of methods to reduce the possibility of their becoming pregnant. Nevertheless, no method of birth control av...

Read the Birth Control (Types and Options) article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Ortho Evra User Reviews >>

Ortho Evra

Birth Control Slideshow Pictures

font size

OVERDOSE

Serious ill effects have not been reported following accidental ingestion of large doses of hormonal contraceptives. Overdosage may cause nausea and vomiting, and withdrawal bleeding may occur in females. Given the nature and design of the ORTHO EVRA® patch, it is unlikely that overdosage will occur. Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. In case of suspected overdose, all ORTHO EVRA® patches should be removed and symptomatic treatment given.

CONTRAINDICATIONS

ORTHO EVRA® should not be used in women who currently have the following conditions:

Thrombophlebitis, thromboembolic disorders
A past history of deep vein thrombophlebitis or thromboembolic disorders
Known thrombophilic conditions
Cerebrovascular or coronary artery disease (current or past history)
Valvular heart disease with complications¹⁰³
Persistent blood pressure values of ≥ 160 mm Hg systolic or ≥ 100 mg Hg diastolic^{103, 112}
Diabetes with vascular involvement¹⁰³
Headaches with focal neurological symptoms
Major surgery with prolonged immobilization
Known or suspected carcinoma of the breast or personal history of breast cancer
Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
Undiagnosed abnormal genital bleeding
Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use
Acute or chronic hepatocellular disease with abnormal liver function¹⁰³
Hepatic adenomas or carcinomas
Known or suspected pregnancy
Hypersensitivity to any component of this product

REFERENCES

103. Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Geneva, WHO, Family and Reproductive Health, 1996 (WHO/FRH/FPP/96.9).

112. Chobanian et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42;1206-1252.

113. Dore D, Norman H, Loughlin J, Seeger D. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 81 (2010):408-413.

114. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users [published erratum appears in Obstet Gynecol 2008:111:1449].

115. Dore D, Norman H, Seeger, J. Eligibility criteria in venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Letter to the Editor. Obstetrics & Gynecology 2009; 114(1):175.

Last reviewed on RxList: 1/23/2012
This monograph has been modified to include the generic and brand name in many instances.